Relating to a review of anti-obesity medications by the department of health and human services for purposes of the medical assistance program

Where it is now

1. ✓
   Done: IntroducedFebruary 19, 2025
2. ✓
   Done: SubcommitteeFebruary 19, 2025
3. ✓
   Done: House committeeFebruary 26, 2025
4. ✕
   Stopped: Passes the HouseDied when the General Assembly ended
5. Next: Senate committeeFunnel: by March 20, 2026
6. Next: Passes the Senate
7. Next: To the Governor
8. Next: Signed into law

Died when the session ended The 2026 session adjourned on May 3, 2026, the General Assembly’s last regular session. Bills that didn’t pass both chambers died. What’s a funnel?

What’s in it

This bill relates to the department of health and human services (HHS) review of anti-obesity medication for purposes of the medical assistance program (Medicaid). The bill requires HHS to review anti-obesity medications for effectiveness, comorbidities, cost savings, and eligibility requirements as described in the bill. HHS shall submit a report to the general assembly by December 1, 2025, containing HHS’s findings and proposed eligibility requirements.

From the explanation printed with the bill as introduced, written by the Legislative Services Agency. Amendments adopted later aren’t reflected. Full bill text

House subcommittee

Named February 19, 2025 (as HSB 209). On February 25, 2025 it recommended passage.

• Rep. Brett Barker REmail
• Rep. Chad Ingels REmail
• Rep. Beth Wessel-Kroeschell DEmail

Three legislators hear a bill first and recommend what the committee should do; it’s the best time to weigh in. How to take part

Family tree

Where this legislation came from and where it went: earlier tries, the versions it moved through this Assembly, and later bills built on it.

Earlier and later bills are matched by wording or an identical title; check the text to be sure it’s the same idea.